FDMT

4D Molecular Therapeutics, Inc. [FDMT] Stock Forecast

Q: What is 4D Molecular Therapeutics, Inc. stock symbol ?

4D Molecular Therapeutics, Inc. is a US stock, located in Emeryville of Ca and trading under the symbol FDMT

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

FDMT Stock Summary

Earnings have grown 562.29% per last year.

EPS has been increasing for the past 3 quarters (Quarter statements)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 21.31%

Earnings are expected to fall -100% next year

FDMT has less than 1 year of cash runway

Top 10 Correlated ETFs

FDMT

Top 10 Correlated Stocks

FDMT

In the News

FDMT Financial details

Company Rating

Sell

Market Cap

1.31B

Income

-99.41M

Revenue

20.72M

Book val./share

0.01

Cash/share

0.01

Dividend

Dividend %

Employees

147

Optionable

Shortable

Yes

Earnings

08 May 2024

P/E

-8.72

Forward P/E

PEG

2.13

P/S

37.9

P/B

2.5

P/C

2536

P/FCF

-10.87

Quick Ratio

17.6

Current Ratio

18.07

Debt / Equity

0.05

LT Debt / Equity

0.04

EPS (TTM)

-1.84

EPS next Y

EPS next Q

EPS this Y

-17.31%

EPS next Y

EPS next 5Y

EPS last 5Y

5.22%

Revenue last 5Y

24.29%

Revenue Q/Q

-100.09%

EPS Q/Q

-99.67%

SMA20

-12.9%

SMA50

22.73%

SMA100

125%

Inst Own

83.17%

Inst Trans

0.66%

ROA

-26%

ROE

244%

ROC

-0.31%

Gross Margin

100%

Oper. Margin

-477%

Profit Margin

-429%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

9.44-36.25

52W High

-29.56%

52W Low

+181.78%

RSI

Rel Volume

0.28

Avg Volume

1.23M

Volume

339.77K

Perf Week

-6.42%

Perf Month

-10.26%

Perf Quarter

144.55%

Perf Half Y

153.6%

Beta

2.862

Volatility

0.66%, 2.75%

Prev Close

-5.2%

Price

25.36

Change

-1.48%

FDMT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.26	0.51	0.65	0.1	0.53
Net income per share	-2	-2.12	-2.46	-3.12	-2.58
Operating cash flow per share	-1.39	-1.91	-2.49	-2.68	-1.94
Free cash flow per share	-1.51	-1.95	-2.82	-3.04	-2.01
Cash per share	1.87	10.37	14.79	11.74	7.37
Book value per share	-2.75	9.61	-7.46	-9.72	7.87
Tangible book value per share	-2.75	9.61	-7.46	7.15	7.87
Share holders equity per share	-2.75	9.61	-7.46	-9.72	7.87
Interest debt per share	0	0	0.59	0.3	0.37
Market cap	1.07B	1.11B	608.41M	718.52M	792.78M
Enterprise value	1.02B	829.24M	309.42M	516M	558.34M
P/E ratio	-20.27	-19.56	-8.91	-7.11	-7.86
Price to sales ratio	153.59	81.25	33.73	229.63	38.26
POCF ratio	-29.23	-21.72	-8.8	-8.29	-10.46
PFCF ratio	-26.88	-21.31	-7.78	-7.32	-10.09
P/B Ratio	-14.7	4.31	-2.94	-2.28	2.58
PTB ratio	-14.7	4.31	-2.94	-2.28	2.58
EV to sales	146.48	60.92	17.15	164.91	26.94
Enterprise value over EBITDA	-25.92	-15.02	-4.34	-4.69	-5.21
EV to operating cash flow	-27.88	-16.29	-4.48	-5.95	-7.37
EV to free cash flow	-25.64	-15.97	-3.95	-5.25	-7.11
Earnings yield	-0.05	-0.05	-0.11	-0.14	-0.13
Free cash flow yield	-0.04	-0.05	-0.13	-0.14	-0.1
Debt to equity	0	0	-0.08	-0.05	0.05
Debt to assets	0	0	0.05	0.06	0.04
Net debt to EBITDA	1.26	5.01	4.19	1.84	2.19
Current ratio	4.05	16.88	19.31	14.02	15.65
Interest coverage	0	0	0	17.14	0
Income quality	0.74	0.9	0.97	0.81	0.75
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.99	1.27	1.55	10.52	1.76
Research and developement to revenue	5.54	3.9	3.4	25.65	4.69
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.09	0.02	0.13	0.13	0.04
Capex to revenue	-0.46	-0.07	-0.51	-3.69	-0.13
Capex to depreciation	-3.19	-0.69	-3.02	-2.97	-0.48
Stock based compensation to revenue	0.51	0.37	0.76	5.47	0.95
Graham number	11.13	21.4	20.34	26.14	21.36
ROIC	0.75	-0.22	0.39	0.37	-0.34
Return on tangible assets	-0.91	-0.2	-0.19	-0.39	-0.3
Graham Net	-3.05	9.22	-5.57	10.73	6.55
Working capital	39.55M	265.91M	299.09M	204.78M	277.64M
Tangible asset value	-72.97M	256.39M	-207M	231.34M	307.83M
Net current asset value	-78.7M	250.71M	-245.05M	190M	264.53M
Invested capital	0	0	-0.08	-0.05	0.05
Average receivables	1.05M	1.23M	766.5K	373.5K	350K
Average payables	1.35M	1.77M	3.28M	4.04M	3.42M
Average inventory	0	0	-4.25M	-7.15M	-2.89M
Days sales outstanding	51.1	39.85	0.95	81.66	0
Days payables outstanding	16.44	12.3	575.78	312.51	223.16
Days of inventory on hand	0	0	-1.03K	-544.49	0
Receivables turnover	7.14	9.16	383.79	4.47	0
Payables turnover	22.2	29.68	0.63	1.17	1.64
Inventory turnover	0	0	-0.36	-0.67	0
ROE	0.73	-0.22	0.33	0.32	-0.33
Capex per share	-0.12	-0.04	-0.33	-0.36	-0.07

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.04	0.01	0.01	0.48	0
Net income per share	-0.84	-0.83	-0.77	-0.24	0
Operating cash flow per share	-0.68	-0.85	-0.58	-0.03	0
Free cash flow per share	-0.72	-0.88	-0.6	-0.04	0
Cash per share	6.57	9.89	10.03	7.56	0.01
Book value per share	7.12	-10.49	-9.72	7.81	0.01
Tangible book value per share	7.12	6.68	-9.72	7.81	0.01
Share holders equity per share	7.12	-10.49	-9.72	7.81	0.01
Interest debt per share	0.46	0.44	0.41	0.36	0
Market cap	721.54M	562.52M	692.72M	537.93M	792.78B
Enterprise value	685.31M	376.34M	398M	277.41M	792.54B
P/E ratio	-6.61	-5.16	-5.85	-13.11	-6.14K
Price to sales ratio	578.62	1.89K	2.9K	26.62	-41.73M
POCF ratio	-32.48	-20.16	-31.39	-459.37	-32.16K
PFCF ratio	-30.96	-19.45	-30.29	-341.32	-31.46K
P/B Ratio	3.12	-1.64	-1.86	1.63	2.58K
PTB ratio	3.12	-1.64	-1.86	1.63	2.58K
EV to sales	549.57	1.26K	1.67K	13.73	-41.71M
Enterprise value over EBITDA	-25.07	-12.5	-12.39	-22.05	-22.55K
EV to operating cash flow	-30.85	-13.49	-18.04	-236.9	-32.15K
EV to free cash flow	-29.4	-13.01	-17.4	-176.02	-31.45K
Earnings yield	-0.04	-0.05	-0.04	-0.02	0
Free cash flow yield	-0.03	-0.05	-0.03	0	0
Debt to equity	0.07	-0.05	-0.04	0.05	0.05
Debt to assets	0.06	0.06	0.04	0.04	0.04
Net debt to EBITDA	1.33	6.18	9.17	20.71	6.67
Current ratio	14.02	18.36	22.57	18.07	15.65
Interest coverage	23.26	21.32	0	0	-25.96
Income quality	0.81	0.97	0.75	0.11	0.76
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	6.79	26.82	36.78	0.45	-558.16
Research and developement to revenue	17.24	75.21	98.68	1.24	-1.37K
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.05	0.04	0.04	0.35	0.02
Capex to revenue	-0.88	-3.4	-3.37	-0.02	28.89
Capex to depreciation	-0.79	-0.72	-0.56	-0.29	-0.36
Stock based compensation to revenue	3.49	14.16	20.79	0.23	-311.21
Graham number	11.6	14.02	13	6.53	0.01
ROIC	-0.11	0.09	0.09	-0.02	-0.13
Return on tangible assets	-0.1	-0.11	-0.08	-0.03	-0.09
Graham Net	5.64	9.12	-8.89	6.82	0.01
Working capital	204.78M	195.76M	296.59M	310.08M	277.64M
Tangible asset value	231.34M	218.61M	-372.79M	329.93M	307.83M
Net current asset value	190M	181.63M	-414.95M	296.56M	264.53M
Invested capital	0.07	-0.05	-0.04	0.05	0.05
Average receivables	350K	350K	0	0	0
Average payables	2.4M	2.87M	2.95M	4.1M	4.11M
Average inventory	-350K	-350K	0	0	0
Days sales outstanding	50.52	0	0	0	0
Days payables outstanding	215.4	153.48	220.15	303.85	74.68
Days of inventory on hand	-45.39	0	0	0	0
Receivables turnover	1.78	0	0	0	0
Payables turnover	0.42	0.59	0.41	0.3	1.21
Inventory turnover	-1.98	0	0	0	0
ROE	-0.12	0.08	0.08	-0.03	-0.1
Capex per share	-0.03	-0.03	-0.02	-0.01	0

FDMT Frequently Asked Questions

What is 4D Molecular Therapeutics, Inc. stock symbol ?

4D Molecular Therapeutics, Inc. is a US stock , located in Emeryville of Ca and trading under the symbol FDMT

What is 4D Molecular Therapeutics, Inc. stock quote today ?

4D Molecular Therapeutics, Inc. stock price is $25.36 today.

Is 4D Molecular Therapeutics, Inc. stock public?

Yes, 4D Molecular Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.23M
Market Capitalization 1.31B
Employee 147
CEO Dr. David H. Kirn M.D.
Headquarters EmeryVille,CA,US
IPO Date 2020-12-11
Website https://www.4dmoleculartherapeutics.com

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.